Radiofrequency ablation for the treatment of primary XXXX .

@entity1 @entity5572 @entity82 @entity5 @entity1419 @entity99
OBJECTIVE: We present the results of percutaneous radiofrequency ablation (RFA) in @entity1 with unresectable primary @entity1419 . MATERIALS AND METHODS: From 2000 to 2009, 13 @entity1 with 17 primary @entity1419 underwent RFA at our institution. @entity1419 was unresectable because of poor hepatic reserve due to liver @entity82 in nine @entity1 , extrahepatic extension in two, @entity99 in one, and underlying comorbidities in one. @entity5 had a diameter of less than 3 cm, five were between 3 and 5 cm, and two were larger than 5 cm. Technical effectiveness was defined as the complete ablation of the @entity5 , shown by imaging follow-up 1 month later. Local progression-free survival, overall survival periods, and complications after RFA were also evaluated. RESULTS: Technical effectiveness of RFA was achieved for 15 of the 17 @entity5 (88%), all smaller than 5 cm in diameter. Treatment failure occurred in two @entity1 with large @entity5 (7 and 8 cm). After the 17 RFA sessions, one major complication (6%), a @entity5572 , occurred 1 month later. During follow-up (median, 19.5 months; range, 3.3-82.1 months), nine @entity1 died and four remain alive. Median local progression-free survival and overall survival periods were 32.2 and 38.5 months, respectively. The 1-, 3-, and 5-year survival rates were 85%, 51%, and 15%, respectively. CONCLUSION: RFA may provide successful local @entity5 control in @entity1 with primary @entity1419 of intermediate (3-5 cm) or small (< 3 cm) diameter. RFA for unresectable primary @entity1419 resulted in a median overall survival period of 38.5 months.
